|
? am so vergleicht hier formycon mit coherus biosciences wo haben die blös ihre dämliche recherche her? ganz klar raus aus formy und rein in coherus....
Market Demand
Biosimilars are in high demand worldwide to contain escalating healthcare costs. Estimated to cost between 70 to 80 percent of the innovator biologic, biosimilars offer potential savings in excess of $300 billion by 2029. Health systems and payers are looking to the industry to develop these high-value, lower cost medicines. While certain pharma-industry players have the capabilities to produce biosimilars, they will need to break from old patterns to succeed in the 21st century. The companies with innovative capabilities, flexible and more dynamic business models and a focused purpose are more likely to introduce competition to the marketplace.
Thanks to advances in technology, players with diverse capabilities in biotechnology can work together in unexpected ways. There are new avenues for entering markets through partnerships and new modes of collaboration that enable companies to distribute risks, share costs and achieve market efficiencies.
Coherus BioSciences recognizes the tremendous biosimilars opportunity. Our business model couples the expertise of an elite leadership team with capital-efficient, strategic partnerships, enabling us to achieve clinical, manufacturing and commercial scale.
Elite Leadership Team
Coherus is led by an elite group of industry veterans who developed the first generation of biologics. The community of people around the world with significant experience in developing and launching biologic products is small, and Coherus Biosciences has an abundance of them on the team.
We?ve worked on 100 molecules, developed and manufactured more than 14 licensed products and launched more than 30 products worldwide.
Network of Strategic Partnerships
Coherus believes shared strategic interest spurs collaboration, efficiency and value. This contrasts with the traditional pharma business model of pursuing a global strategy under one umbrella. Coherus has developed a unique, collaborative business model that leverages a strategic consortium of key service providers aligned through ownership and shared incentives. With its flat and nimble hierarchical structure, Coherus is able to manage laterally ? executing development paths in parallel with its partners ? to shorten timelines and speed biosimilar therapeutics to market.
Coherus? collaborative, seamless network of strategic and financial partnerships allows the company to compete with much larger players while deploying invested capital efficiently. To project scale when necessary we employ:
Collaborative model: We retain only core competencies in-house and outsource or partner the rest. This provides the flexibility to engage specific expertise, technologies and facilities as needed.
World-class partners: Coherus works with a multi-functional syndicate of strategic partners, including technology platform (Selexis and Legacy BioDesign), clinical development (Medpace), manufacturing (Rentschler and Cook), biopharma (Daiichi Sankyo and Baxter International) and multiple investment companies to achieve clinical, manufacturing and commercial scale.
Licensing strategy: Coherus will commercialize biosimilars in ex-U.S. territories through our licensing and partnership structures, while retaining commercialization rights in North America. This flexible platform is self-sustaining, with licensing relationships providing a long-term profit stream.
With this emphasis on collaboration with partners across the healthcare value chain, Coherus aims to:
Address inefficiencies that have slowed drug development in the past;
Gain access to the most advanced enabling technologies for drug development that are more effective than those used to create biologics a decade ago;
Create long-term relationships with parties that are aligned for the success of Coherus and its products; and
Ultimately, expedite overall speed-to-market while decreasing costs for safe, high-quality biologics.
|
1 |
2 |
3 |
Thread abonnieren
